| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/25/2009 | US7579343 3,4-dihydroxy,2,3,3a-4-tetrahydro-1-H-pyrrolo-[2,1c][1,4]benzothiazine |
| 08/25/2009 | US7579342 Pteridine compounds for the treatment of psoriasis |
| 08/25/2009 | US7579341 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
| 08/25/2009 | US7579340 Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation; inflammatory bowel disease |
| 08/25/2009 | US7579339 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| 08/25/2009 | US7579338 Motexafin gadolinium, acetic acid, and water |
| 08/25/2009 | US7579337 Analogs of benzoquinone-containing ansamycins and methods of use thereof |
| 08/25/2009 | US7579336 Pharmaceutical composition comprising temozolomide ester |
| 08/25/2009 | US7579335 e.g. Cyanomethyl (6 alpha ,11 beta ,16 alpha ,17 alpha )-17-({[(1,1-dimethylethyl)oxy]carbonyl}oxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylate; glucocorticoid receptor agonists of the androstane series; with other beta 2-adrenoreceptor agonist; asthma, rhinitis, eczema |
| 08/25/2009 | US7579334 Compounds with anti-inflammatory activity |
| 08/25/2009 | US7579333 for the treatment of osteoporosis, metastatic bone disease, or Paget's disease; reduce ulcerative side effect; dosage forms |
| 08/25/2009 | US7579332 Nucleobase phosphonate analogs for antiviral treatment |
| 08/25/2009 | US7579331 Method of improved diuresis in individuals with impaired renal function |
| 08/25/2009 | US7579330 Methods of treating various cancers using melanoma differentiation associated protein-7 |
| 08/25/2009 | US7579329 P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof |
| 08/25/2009 | US7579327 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators |
| 08/25/2009 | US7579326 Gene switch systems employing regulators with decreased dimerization |
| 08/25/2009 | US7579325 Drugs containing reduced of vitamin B2 |
| 08/25/2009 | US7579324 Carrier, linker and nonantibiotic therapeutic agent; small molecules; bioavailability, efficacy |
| 08/25/2009 | US7579313 Transglutaminase inhibitors and methods of use thereof |
| 08/25/2009 | US7579141 Method of in vitro diagnosis which discriminates between exposure of a subject to Mycobacterium tuberculosis and vaccination with Bacille Calmette Guerin strain of Mycobacterium bovis, method comprising testing for presence of CD4 T lymphocytes that respond to MTBN4 |
| 08/25/2009 | US7579023 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals |
| 08/25/2009 | US7579020 Controlled release arginine α-ketoglutarate |
| 08/25/2009 | US7579016 Treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog and optionally a carrier or carrier material; tricyclo(1S,8S)-2,2,7,7-tetramethyltricyclo[6.2.1.01,6]undecane derivative |
| 08/25/2009 | US7579015 improved average foam stability; surfactant, dimer acid, an (olefin) block copolymer, an oil or fat and water |
| 08/25/2009 | US7579006 Method of treating immune pathologies with low dose estrogen |
| 08/25/2009 | CA2563965C 6-0-substituted ketolides having antibacterial activity |
| 08/25/2009 | CA2538072C Amide-type carboxamide derivatives |
| 08/25/2009 | CA2505086C Ophthalmic compositions for treating ocular hypertension |
| 08/25/2009 | CA2488976C Inhalable epinephrine |
| 08/25/2009 | CA2474578C Novel pyridin- and pyrimidin-derivatives |
| 08/25/2009 | CA2439078C Composition improving age-related physiological deficits and increasing longevity |
| 08/25/2009 | CA2430281C Use of weak opioids and mixed opioid agonists/antagonists for treatment of urinary incontinence |
| 08/25/2009 | CA2426680C Process for formulation of antibiotic compounds |
| 08/25/2009 | CA2414967C Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 08/25/2009 | CA2413775C A combination kit used in the treatment of malaria |
| 08/25/2009 | CA2405172C Alpha,beta-unsaturated sulfones for treating proliferative disorders |
| 08/25/2009 | CA2402708C Torasemide-containing pharmaceutical preparations |
| 08/25/2009 | CA2394794C Methods for preparing pharmaceutical formulations |
| 08/25/2009 | CA2388163C Process for formulation of carbapenem antibiotic compositions |
| 08/25/2009 | CA2383466C Aromatic nitrogen-containing 6-membered cyclic compounds |
| 08/25/2009 | CA2382521C Oligonucleotide n3'.fwdarw.p5' thiophosphoramidates: their synthesis and use |
| 08/25/2009 | CA2375671C 4-phenyl-pyrimidine derivatives |
| 08/25/2009 | CA2372456C Viral infection inhibitor targeting integrase n-terminal domain |
| 08/25/2009 | CA2368356C Patches containing buprenorphine hydrochloride |
| 08/25/2009 | CA2366932C Cyclic protein tyrosine kinase inhibitors |
| 08/25/2009 | CA2327673C Aminopiperidine derivatives as integrin .alpha.v.beta.3 antagonists |
| 08/25/2009 | CA2326815C Process for preparation of pyridine derivatives |
| 08/25/2009 | CA2269246C Substituted tricyclics |
| 08/25/2009 | CA2234500C Novel biologically active silicon-based compositions |
| 08/25/2009 | CA2215356C Novel embolizing compositions |
| 08/24/2009 | CA2598095A1 Method of relieving or avoiding side effect of steroid |
| 08/22/2009 | CA2619029A1 New cell technologies |
| 08/20/2009 | WO2009103076A1 Methods and compositions for enhancing the efficacy of rtk inhibitors |
| 08/20/2009 | WO2009103072A2 Erbb4 inhibitors and uses thereof in treatment of neuropsychiatric disorders |
| 08/20/2009 | WO2009103069A1 Skin penetration enhancing systems for polar drugs |
| 08/20/2009 | WO2009103057A2 Polyglycerol sebecate peritoneal adhesion prevention barrier |
| 08/20/2009 | WO2009103053A1 Fluoroquinolone derivatives for ophthalmic applications |
| 08/20/2009 | WO2009103035A2 Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| 08/20/2009 | WO2009103032A1 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| 08/20/2009 | WO2009103007A2 Steroid hormone receptor modulator compounds and methods |
| 08/20/2009 | WO2009103004A1 Selective opioid compounds |
| 08/20/2009 | WO2009102997A2 Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase |
| 08/20/2009 | WO2009102986A1 Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor |
| 08/20/2009 | WO2009102960A1 Compositions and methods for treating lung cancer |
| 08/20/2009 | WO2009102931A1 Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions |
| 08/20/2009 | WO2009102928A2 Methods for the preparation of p1 - alkoxyphenyl - ribofuranoside, p4 -adenosine tetraphosphate derivatives |
| 08/20/2009 | WO2009102895A2 Method to predict response to pharmacological chaperone treatment of diseases |
| 08/20/2009 | WO2009102886A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 08/20/2009 | WO2009102876A1 Macrocyclic inhibitors of hepatitis c protease |
| 08/20/2009 | WO2009102864A1 Hedgehog pathway antagonists and methods of use |
| 08/20/2009 | WO2009102845A2 Food products containing omega-3 fatty acids |
| 08/20/2009 | WO2009102814A2 Mucosally non-irritative liquid amphotericin b formulations and methods for treating non-invasive fungus-induced mucositis |
| 08/20/2009 | WO2009102808A2 Doxorubicin adjuvants to reduce toxicity and methods for using the same |
| 08/20/2009 | WO2009102805A1 Indole compounds and methods of use thereof |
| 08/20/2009 | WO2009102795A1 Monomers and polymers with covalently-attached active ingredients |
| 08/20/2009 | WO2009102789A2 Use of rxr agonists for the treatment of osteroarthritis |
| 08/20/2009 | WO2009102778A1 Amorphous polymorph of bazedoxifene acetate |
| 08/20/2009 | WO2009102773A1 Methods of preparing polymorphic form a of bazedoxifene acetate |
| 08/20/2009 | WO2009102771A1 Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate |
| 08/20/2009 | WO2009102761A1 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 08/20/2009 | WO2009102734A1 Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form |
| 08/20/2009 | WO2009102694A1 Heterocyclic derivatives as hepatitis c virus inhibitors |
| 08/20/2009 | WO2009102633A1 Hepatitis c virus inhibitors |
| 08/20/2009 | WO2009102588A1 Fused pyridone m1 receptor positive allosteric modulators |
| 08/20/2009 | WO2009102574A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 08/20/2009 | WO2009102570A2 Treatments for neuropathy |
| 08/20/2009 | WO2009102568A1 Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors |
| 08/20/2009 | WO2009102497A2 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species |
| 08/20/2009 | WO2009102496A2 Selective agonist of toll-like receptor 3 |
| 08/20/2009 | WO2009102478A1 Inhibition of angiogenesis |
| 08/20/2009 | WO2009102468A1 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| 08/20/2009 | WO2009102465A2 Continuous cell programming devices |
| 08/20/2009 | WO2009102462A1 Thienopyrroles and pyrrolothiazoles as new therapeutic agents |
| 08/20/2009 | WO2009102443A2 Octanoic acid formulations and methods of treatment using the same |
| 08/20/2009 | WO2009102433A2 Compounds with mdr1-inverse activity |
| 08/20/2009 | WO2009102428A2 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
| 08/20/2009 | WO2009102427A2 Modified rnai polynucleotides and uses thereof |
| 08/20/2009 | WO2009102418A1 Methods for the treatment and prevention of age-related retinal dysfunction |
| 08/20/2009 | WO2009102325A1 Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |